<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>For clinical studies with erythropoietin (EPO), enzyme-linked immunosorbent assays for the determination of EPO and EPO antibodies were developed </plain></SENT>
<SENT sid="1" pm="."><plain>Using polyclonal and monoclonal EPO antibodies in a sandwich technique, serum EPO levels greater than 10 pg/ml (corresponding to 1 mU/ml, calibrated with the 2nd WHO IRP EPO) can be determined </plain></SENT>
<SENT sid="2" pm="."><plain>In 103 healthy blood donors, a mean (+/- SD) value of 36 +/- 19 pg EPO/ml was found </plain></SENT>
<SENT sid="3" pm="."><plain>Very high EPO concentrations were found in patients suffering from <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>; elevated levels were associated with <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> and <z:e sem="disease" ids="C0026764" disease_type="Neoplastic Process" abbrv="">myelomatosis</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>No EPO antibodies were detectable in EPO-treated patients </plain></SENT>
</text></document>